Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes
Condition: T2DM Interventions: Drug: CSII+Vildagliptin; Drug: CSII(insulin Lispro) Sponsor: The First Affiliated Hospital of Xiamen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials